Results 11 to 20 of about 9,786 (244)

Efficacy and Safety of Deferasirox [PDF]

Oncology & Hematology Review (US), 2009
Deferasirox represents a new class of once-daily iron chelators. It was first licensed in 2005 for the treatment of adult and pediatric patients with chronic iron overload due to blood transfusions. These approvals were based on data from the core program of one-year clinical trials, which involved more than 1,000 patients in what is the largest and ...
Maria Domenica Cappellini, Laura Zanaboni   +1 more
openalex   +3 more sources

Signs of deferasirox genotoxicity [PDF]

Cytotechnology, 2013
Iron overload is a major health problem for patients who have to have continuous blood transfusions. It brings some metabolic problems together. Various iron chelating agents are being used for treatment of hemochromatosis which arises from excess iron accumulation.
Hasan Basri İla, Mehmet Topaktaş, Mehmet Arslan, Mehmet Büyükleyla   +3 more
openalex   +7 more sources

Complex interaction of deferasirox and Pythium insidiosum: iron-dependent attenuation of growth in vitro and immunotherapy-like enhancement of immune responses in vivo. [PDF]

PLoS ONE, 2015
Pythium insidiosum iron acquisition mechanisms are unknown. We previously showed that the iron chelator deferasirox had weak activity in vitro and in rabbits with experimental pythiosis. Here we show that deferasirox causes damage to P. insidiosum hyphae
Régis A Zanette, Paula E R Bitencourt, Dimitrios P Kontoyiannis, Rafael A Fighera, Mariana M Flores, Glaucia D Kommers, Priscila S Silva, Aline Ludwig, Maria B Moretto, Sydney H Alves, Janio M Santurio   +10 more
doaj   +3 more sources

Deferasirox: appraisal of safety and efficacy in long-term therapy

Journal of Blood Medicine, 2013
Preeti Chaudhary, Vinod PullarkatJane Ann Nohl Division of Hematology, University of Southern California Keck School of Medicine, Los Angeles, CA, USAAbstract: Deferasirox is a once-daily, oral iron chelator that is widely used in the management of ...
Chaudhary P, Pullarkat V
doaj   +3 more sources

Deferasirox in mucormycosis: hopefully, not defeated [PDF]

Journal of Antimicrobial Chemotherapy, 2011
R. Soman, Neha Gupta, Anjali Shetty, Camilla Rodrigues   +3 more
openalex   +4 more sources

Deferasirox in Indian children with thalassemia major: 3 years experience [PDF]

Indian Journal of Medical and Paediatric Oncology, 2013
Objective: To evaluate the efficacy and safety of the oral iron chelator deferasirox in treating transfusional hemosiderosis in a cohort of Indian children with thalassemia major with high iron load. Materials and Methods: The first 50 children (age 2-18
Mayank Dhamija, Amita Mahajan, Manas Kalra, Anju Virmani   +3 more
doaj   +2 more sources

Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions

Therapeutics and Clinical Risk Management, 2016
Anna W Chalmers, Jamile M Shammo Department of Internal Medicine, Division of Hematology/Oncology, Rush University Medical Center, Chicago, IL, USA Abstract: Transfusion-dependent anemia is a common feature in a wide array of hematological disorders ...
Chalmers AW, Shammo JM
doaj   +3 more sources

Extracorporeal Blood Purification Therapy to Deal a Deferasirox Induced Life-Threatening Hepatic Encephalopathy in a Septic Child With Sickle-Cell Disease: A Case Report. [PDF]

J Clin Apher
ABSTRACT This report details a rare pediatric case of hyperammonemic encephalopathy caused by the oral iron chelating drug deferasirox (DFR) in a septic patient. It is our contention that this study lends support to the existing literature, as it describes the case of a 15‐year‐old female patient with a history of sickle‐cell disease who presented with
Rossetti E, Cappoli A, Labbadia R, Leone G, Chiusolo F, Tortora F, Martinelli D, Marano M.   +7 more
europepmc   +2 more sources

Deferasirox Derivatives as Inhibitors of Kallikrein-Related Peptidases Associated to Neurodegenerative Diseases. [PDF]

ChemMedChem
Dysregulated proteolysis mediated by kallikrein‐related peptidases (KLKs) and iron overload are involved in the progression of neurodegenerative diseases. Deferasirox, an clinically‐approved iron chelator, and its newly synthesized derivatives have been identified as inhibitors of major central nervous system KLKs with low cytotoxicity and effective ...
Boumali R, David E, Chaaya N, Lucas M, Aït Amiri S, Lefort V, Nina-Diogo A, Salmain M, Petropoulos I, Corcé V, El Amri C, Botuha C.   +11 more
europepmc   +2 more sources

Update on the use of deferasirox in the management of iron overload

Therapeutics and Clinical Risk Management, 2009
Ali Taher,1 Maria Domenica Cappellini21American University of Beirut, Beirut, Lebanon; 2Universitá di Milano, Policlinico Foundation IRCCS, Milan, ItalyAbstract: Regular blood transfusions as supportive care for patients with chronic anemia ...
Ali Taher, Maria Domenica Cappellini
doaj   +6 more sources